MV4-11 cell line (MV4-11)

MV4-11 is a human cell line established from the blast cells of a 10-year-old male with biphenotypic B-myelomonocytic leukemia (ATCC, 2024). It is a widely utilized model in preclinical oncology research, particularly for Acute Myeloid Leukemia (AML), due to its specific genetic profile (Cellosaurus, 2024). The line is characterized by a chromosomal translocation, t(4;11)(q21;q23), which produces the MLL-AF4 fusion protein (Quentmeier et al., 2003). Additionally, it carries a homozygous internal tandem duplication of the FLT3 gene (FLT3-ITD), leading to constitutive kinase activity (Levis, 2017). Because it exhibits constitutive activation of the FLT3 signaling pathway, MV4-11 serves as a primary in vitro and in vivo model for evaluating the efficacy of FLT3 tyrosine kinase inhibitors like midostaurin and gilteritinib (Levis, 2017). While it is an essential tool for drug screening and understanding leukemogenesis, it represents a complex biological system rather than a single therapeutic target molecule. Researchers frequently use this line to study the mechanisms of drug resistance and the downstream signaling pathways of MLL rearrangements.

Other names

MV4;11MV-4-11MV(4;11)

Not applicable; MV4-11 is a cell line model used to evaluate drugs targeting FLT3 and MLL-rearranged pathways.